[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sensory-deficit\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sensory-deficit":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100591053","walking-sensation-study-100591053",false,"NCT06975423","Walking Sensation Study","Somatosensory Feedback to Improve Neural Control of Walking in Older Adults","Inclusion Criteria:\n\n* Not having any significant existing medical conditions, historical health issues, or medications (outlined in the exclusion criteria table above) that could impede the execution of the walking task and assessment.\n* age 65 - 95.\n* no severe high blood pressure (systolic \\\u003C 180 mmHg and\u002For diastolic \\\u003C 100 mmHg at rest).\n* no severe vision impairment: visual acuity ≥ 20\u002F70 as determined by Snellen eye chart.\n* slow walking speed: preferred walking speed slower than 1.0 m\u002Fs over 10 meter.\n* no cognitive impairment: Montreal Cognitive Assessment (MoCA) score ≥ 26 out of 30 possible points.\n* foot sensory impairment: Inability to feel the 10 g monofilament at ≥1 of 10 tested sites on either foot is considered a sign of impaired protective sensation. loss.\n\nExclusion Criteria:\n\n* diagnosed neurological disorder or injury of the central nervous system, or observation of symptoms consistent with such a condition (Alzheimer's, Parkinson's, stroke, etc.)\n* severe arthritis, such as awaiting joint replacement\n* current cardiovascular, lung or renal disease; untreated diabetes; terminal illness\n* myocardial infarction or major heart surgery in the previous year\n* cancer treatment in the past year, except for nonmelanoma skin cancers and cancers having an excellent prognosis (e.g., early stage breast or prostate cancer)\n* current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder\n* currently taking medications that affect the central nervous system, such as benzodiazepines, anti-cholinergic medication, and GABAergic medication, among others\n* no severe vision impairment (visual acuity ≥ 20\u002F70 as determined by Snellen eye chart)\n* uncontrolled hypertension at rest (systolic \\> 180 mmHg and\u002For diastolic \\> 100 mmHg)\n* bone fracture or joint replacement in the previous six months\n* current enrollment in any other clinical trial\n* planning to relocate out of the area during the study period\n* non-English\\* speaking, due to the likelihood of difficulties following instructions and communicating remotely\n* clinical judgment of the investigative team",true,"ALL","65 Years","95 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective of this new line of research is to test whether augmenting sensory information from the legs, using Walkasins sensory neuroprosthesis, can enhance performance of a complex walking task in older adults with foot sensory impairment. The overarching hypothesis is that Walkasins will enhance the automaticity and reduce cognitive demand of walking in older adults with foot sensory impairments, as measured by reduced prefrontal activity, decreased dual-task costs, and lower gait variability.",[28,29],"Aging","Sensory Deficit",[31,32,33],"Dual-task walking","Brain activity","Walking performance","RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":38},"2025-09-08",{"date":42,"type":22},"2027-03-31",{"name":44,"class":45},"University of Florida","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":46},"100590052","effectiveness-of-active-exploration-of-simulated-textures-for-sensorimotor-recovery-100590052","NCT06962397","Effectiveness of Active Exploration of Simulated Textures for Sensorimotor Recovery","Research on the Effectiveness of the Method of Active Examination of Artificially Simulated Textures Generated by Programmable Transcutaneous Electrical Stimulation as a Method of Restoring Sensorimotor Function of the Upper Limbs","Inclusion Criteria:\n\n* Episode of stroke confirmed by neuroimaging\n* More than one month post-stroke\n* Montreal Cognitive Assessment (MoCA) score ≥ 20\n* Barthel Index score ≥ 3\n* Ability to understand and follow instructions\n* Informed consent for participation and data collection\n* Age 18-80 years\n\nExclusion Criteria:\n\n* Presence of depressive symptoms (HADS-Depression \\> 11)\n* Upper limb paresis score below 35 on the Fugl-Meyer scale\n* Sensory impairment score below 3 or above 10 on the Fugl-Meyer scale","18 Years","80 Years",{"count":57,"type":22},20,[25],"Parallel-group, single-blinded controlled clinical trial. The study includes people aged 18-80 years, more than one month after stroke, with confirmed diagnosis, MoCA ≥ 20, and Barthel Index ≥ 3.\n\nThe control group receives standard rehabilitation. The experimental group also receives active sensory training with programmable electrical stimulation to simulate virtual textures.\n\nSensory function was assessed before and after the training using standard tests, including Fugl-Meyer, ARAT, 9HPT, and monofilament testing.",[61,62,29,63,64],"Stroke","Sensorimotor Impairment Affecting the Upper Limb","Rehabilitation","Tactile Disorders",[61,66,67,68,69,70,71,72,73,74,75,76,77,78],"Sensorimotor rehabilitation","Tactile stimulation","Upper limb recovery","Electrical stimulation","Virtual textures","Sensory training","Neurorehabilitation","Post-stroke therapy","Active touch paradigm","Functional electrical stimulation","Proprioception","Touch sensitivity","Stroke rehabilitation technology","2025-05-19",{"date":81,"type":38},"2025-05-22",{"date":83,"type":38},"2024-10-08",{"date":85,"type":22},"2026-01",{"name":87,"class":45},"Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health"]